Article placeholder black
Cognito Therapeutics to Present Clinical Data Evaluating Gamma Frequency Neuromodulation in Alzheimer’s Disease at 2022 CTAD Conference
Article placeholder black
Cognito's light-and-sound therapy slows brain tissue atrophy in Alzheimer's study
Article placeholder black
Cognito Therapeutics Announces Proprietary Gamma Sensory Stimulation for 6-Months Reduces White Matter Atrophy in Alzheimer’s Disease Patients
Article placeholder black
Cognito Therapeutics Announces Data Presentations at the Alzheimer’s Association International Conference 2022
article placeholder
Cognito Therapeutics Joins Digital Medicine Society’s (DiMe) Alzheimer's Disease and Related Dementias Project to Advance Next-Generation Clinical Measures
Economist77
Some health apps are able not just to diagnose diseases, but also to treat them
Article placeholder black
Gamma Sensory Stimulation Demonstrates Efficacy in Alzheimer Disease in New Analysis
article placeholder
With pharma still struggling in Alzheimer’s, health tech companies want a swing
article placeholder
Ushering in a New Class of Disease-Modifying DTx
Healio media
Cognito Therapeutics, Aetion to partner on AI model that identifies AD patients
article placeholder
Cognito Therapeutics and Aetion Announce Partnership to Use Artificial Intelligence to Identify Rapidly Progressing Forms of Mild Cognitive Impairment and Alzheimer's Disease
article placeholder
Fierce Medtech Names Cognito Therapeutics as One of Its “Fierce 15” Med Tech Companies of 2021
Fierce 15
Fierce Medtech's 2021 Fierce 15
article placeholder
Cognito Therapeutics Announces Presentations for Novel Therapeutic in Alzheimer’s Disease at the 2022 American Academy of Neurology (AAN) Conference
article placeholder
Cognito Therapeutics to Present Virtual Symposium “Predicting Alzheimer’s Disease Progression with Neurophysiological Markers” at 2022 AD/PD Conference
article placeholder
Cognito Therapeutics and Providence Health Plan Launch Phase 3 Study to Evaluate Disease-Modifying Therapeutic in Mild Cognitive Impairment
article placeholder
Cognito Therapeutics Appoints Jennifer Newberger as Head of Regulatory and Compliance
article placeholder
Digital Therapeutics Alliance Elects Cognito Therapeutics’ Everett Crosland to its Board of Directors
article placeholder
Cognito Therapeutics CEO Brent Vaughan to Speak at CODE Conference 2021
article placeholder
Cognito Therapeutics Announces Formation of Payor Advisory Board
article placeholder
Cognito Therapeutics to Participate in the BTIG Virtual Biotechnology Conference 2021
article placeholder
Cognito Therapeutics Presents New Clinical Data Demonstrating Disease-Modifying Effects of Gamma Frequency Neuro-modulation on Cognitive Function and Brain Atrophy in Alzheimer’s Disease at AAIC 2021
article placeholder
Cognito Therapeutics Announces Upcoming Data Presentations at the Alzheimer’s Association International Conference 2021
article placeholder
Cognito Therapeutics Appoints Gerald Chan as Chairman of the Board
article placeholder
Cognito Therapeutics Initiates Studies in Down Syndrome Associated Alzheimer’s Disease
article placeholder
Cognito Therapeutics Appoints Everett Crosland as Chief Commercial Officer
article placeholder
Cognito Therapeutics Appoints Jonathan Lieber as Chief Financial Officer
article placeholder
Cognito Therapeutics to Advance Digital Therapeutic for Alzheimer’s into Pivotal Studies Based on Positive Clinical Results Announced at AD/PD 2021
article placeholder
Cognito Therapeutics Announces Positive Phase 2 Results as First Digital Therapeutic to Improve Memory, Cognition, Functional Abilities and Reduce Brain Atrophy in Alzheimer’s Disease
article placeholder
Cognito Therapeutics to Announce New Clinical Data Evaluating Gamma Frequency Neuromodulation to Treat Alzheimer’s Disease at 2021 AD/PD Virtual Conference
article placeholder
Cognito Therapeutics Appoints Mark Day, Ph.D., as Chief Business Officer
article placeholder
Cognito Therapeutics Receives FDA Breakthrough Device Designation for Next-Generation Digital Therapeutic in Alzheimer’s Disease
article placeholder
Cognito Therapeutics Appoints Industry Pioneer Brent Vaughan as Chief Executive Officer